News

FDA approves HIV prevention drug taken as twice-yearly injection
Clinical trials showed 99.9% of participants who received the drug, called Yeztugo​ from company Gilead Sciences, remained ...
Gilead Sciences' Twice-Yearly HIV-Prevention Drug Gets FDA Approval
The drug, known as Yeztugo, is the first and only twice-yearly option available in the U.S. for people who need or want PrEP, Gilead said Wednesday. Just under 100% of patients who received the drug ...
Yeztugo® (Lenacapavir) Is Now the First and Only FDA-Approved HIV Prevention Option Offering 6 Months of Protection
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Yeztugo® ...
Australian Red Cross Lifeblood loosens rules around LGBTQIA+ donating blood and plasma
Restrictions around sexually active gay and bisexual men donating blood and plasma are being loosened in a new world-leading ...
jme.bmj4d
The transplantation of solid organs from HIV-positive donors to HIV-negative recipients: ethical implications
But the question of whether HIV-negative patients should be disallowed from receiving an organ from an HIV-positive donor has not been adequately explored. In this essay, we will discuss the ...
Physician's Weekly5d
Q&A: Addressing Cost & Modality to Increase PrEP Use in Diverse Populations
Shahin Davoudpour, PhD, MA, MA, discusses the challenges associated with access to and persistence with pre-exposure ...